Breaking News, Financial News

Financial Reports: Biogen Idec 2Q11

Tysabri revenues climb 28%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 2Q 2Q Revenues: $1.2 billion (flat) 2Q Earnings: $304.0 million (+3%) YTD Revenues: $2.4 billion (+4%) YTD Earnings: $612.8 million (+19%) Comments: Tysabri revenues were up 28% to $281 million in the quarter. Avonex sales were $659 million (+5%). Rituxan revenues from the joint partnership with Genentech were $216 million in the quarter, down 29% due to ongoing arbitration between Genentech and Hoechst GmbH. Revenues from other products were $16 million, up 36%. Royalties were ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters